Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Soo
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(62)
•••
Comment by WalkOverTheStrton Jun 04, 2020 10:33pm
194 Views
Post# 31114633

RE:RE:RE:RE:Soo

RE:RE:RE:RE:Soomarf49 it's a little naive to think a partnership would be announced the same day let alone same week as the top line PH2B data.... I think you are reaching there...

This data just further opened the door to every major biotech on the planet... they now have the efficacy data to back up the safety component of the drug. They also hired a very seasoned CMO who worked at the FDA during Viox and CELEBREX.... perepctive, listen to his comments.. 

Maybe you haven't watched Dan prior, but recommend watching his other dozen plus of interviews... one poor showing doesnt make a poor leader and to put it in context this during an interesting time...

I'll buy more on dips, this is a $1B MC company that retail is too naive and lacking in critical thinking to see. Wait till it lists on a major exhange and games really start to throw retail off this rocket...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities